Danaher Corporation (NYSE:DHR) Announces $0.32 Quarterly Dividend

Key Points

• Danaher Corporation announced a quarterly dividend of $0.32 per share, to be paid on October 31st, with stockholders of record on September 26th.
• The company has a low dividend payout ratio of 14.9%, indicating that its dividend is well-covered by earnings.
• Danaher's stock price fell by 2.2% to $194.24, while the company's market capitalization stands at approximately $139.09 billion.

Danaher Corporation (NYSE:DHR - Get Free Report) announced a quarterly dividend on Tuesday, September 9th, RTT News reports. Stockholders of record on Friday, September 26th will be paid a dividend of 0.32 per share by the conglomerate on Friday, October 31st. This represents a c) dividend on an annualized basis and a dividend yield of 0.7%.

Danaher has a payout ratio of 14.9% meaning its dividend is sufficiently covered by earnings. Research analysts expect Danaher to earn $8.57 per share next year, which means the company should continue to be able to cover its $1.28 annual dividend with an expected future payout ratio of 14.9%.

Danaher Stock Down 2.2%

Shares of Danaher stock traded down $4.39 during trading on Tuesday, reaching $194.24. The stock had a trading volume of 3,344,891 shares, compared to its average volume of 4,138,028. The company has a market capitalization of $139.09 billion, a price-to-earnings ratio of 41.33, a P/E/G ratio of 2.79 and a beta of 0.75. The stock has a fifty day moving average price of $201.95 and a two-hundred day moving average price of $199.23. Danaher has a 52 week low of $171.00 and a 52 week high of $279.90. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, beating analysts' consensus estimates of $1.64 by $0.16. The company had revenue of $5.94 billion for the quarter, compared to analyst estimates of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The company's quarterly revenue was up 3.4% compared to the same quarter last year. During the same period in the previous year, the company posted $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Sell-side analysts predict that Danaher will post 7.63 EPS for the current fiscal year.

Analyst Ratings Changes

DHR has been the topic of a number of recent research reports. UBS Group lowered their target price on Danaher from $240.00 to $225.00 and set a "buy" rating on the stock in a research report on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft lowered their target price on Danaher from $240.00 to $235.00 in a research report on Thursday, June 5th. Royal Bank Of Canada set a $241.00 target price on Danaher in a research report on Tuesday, September 2nd. Evercore ISI lowered their target price on Danaher from $230.00 to $226.00 and set an "outperform" rating on the stock in a research report on Tuesday, July 8th. Finally, Wall Street Zen raised Danaher from a "hold" rating to a "buy" rating in a research report on Friday, June 27th. Seventeen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $246.35.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.